Efficacy of neoadjuvant chemotherapy for initially resectable colorectal liver metastases: A retrospective cohort study

doi:10.4251/wjgo.v14.i7.1281

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4748)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-5) series.

Item

Count

PDF

201

WORD

HTML

1559

Figures (1-3)

270

Tables (1-5)

225

Sum=2308

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

260

Download

628

Sum=888

Publishing Process of This Article

Item

Count

Browse

394

Download

1158

Sum=1552

Jul 15, 2022 (publication date) through Jan 27, 2025

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Control Study

World J Gastrointest Oncol. Jul 15, 2022; 14(7): 1281-1294
Published online Jul 15, 2022. doi: 10.4251/wjgo.v14.i7.1281

Table 5 Initial treatment strategy for recurrence in high-risk patients

Case	NAC regimen	Course	Efficacy	First recurrence site	Initial treatment for recurrence	Conversion
Case	NAC regimen	Course	Efficacy	First recurrence site	Initial treatment for recurrence	Therapy
1	FU, FOL + CDDP	2	SD	Peritoneum	LV/5-FU + CPT-11 (IFL)	Resection
2	FU, FOL + CDDP	2	SD	Liver	LV/5-FU + CPT-11 (IFL)	Resection
3	FU, FOL	2	PD	Other	FOLFOX + Bmab
4	FU, FOL + CDDP	4	SD	Lung	Resection
5	FOLFOX + Bmab	8	PD	Liver	FOLFIRI + Bmab	Resection
6	XELOX + Bmab	14	SD	Lung	IRIS + Bmab
7	FOLFOX + Cmab	6	PR	Liver	Resection
8	IRI + Pmab	6	PR	Peritoneum	IRI + Pmab
9	FOLFIRI + Bmab	6	PR	Liver	FOLFIRI + Bmab

Bmab: Bevacizumab; CDDP: Cisplatin; Cmab: Cetuximab; FOL: Folinic acid; FOLFIRI: Fluorouracil + leucovorin + irinotecan; FOLFOXR: Folinic acid + fluorouracil + oxaliplatin; FU: Fluorouracil; IFL: I-leucovorin + fluorouracil + irinotecan; IRI: Irinotecan; IRIS: Irinotecan + s-1; Pmab: Panitumumab; XELOX: Capecitabine + oxaliplatin; NAC: Neoadjuvant chemotherapy.

Citation: Takeda K, Sawada Y, Yabushita Y, Honma Y, Kumamoto T, Watanabe J, Matsuyama R, Kunisaki C, Misumi T, Endo I. Efficacy of neoadjuvant chemotherapy for initially resectable colorectal liver metastases: A retrospective cohort study. World J Gastrointest Oncol 2022; 14(7): 1281-1294
URL: https://www.wjgnet.com/1948-5204/full/v14/i7/1281.htm
DOI: https://dx.doi.org/10.4251/wjgo.v14.i7.1281